• Explore /
  • Poster
  • / High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.

High dose ipilimumab (Ipi) plus temozolomide (TMZ) after progression on standard or low dose Ipi in advanced melanoma.

Abstract Poster

Authors

null

Julie Williamson

Department of Internal Medicine, University of Utah, Salt Lake City, UT

Julie Williamson , Muhammad Zaki Hidayatullah Fadlullah , Magdalena Kovacsovics , Berit Gibson , Alyssa Erickson-Wayman , Debra Jamison , Daniel S. Sageser , Umang Swami , Joanne M. Jeter , Tawnya Lynn Bowles , Donald Maurice Cannon , Ben Haaland , Joyce Schroeder , Jordan P. McPherson , John Robert Hyngstrom , Aik-choon Tan , Siwen Hu-Lieskovan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9557)

DOI

10.1200/JCO.2023.41.16_suppl.9557

Abstract #

9557

Poster Bd #

320

Abstract Disclosures

Similar Posters

First Author: Ahmad A. Tarhini

First Author: Geoffrey Thomas Gibney

First Author: F. Stephen Hodi

First Author: Ciara Conduit